Menu
The PRECISE Trial – A conversation with Dr. James Udelson, Tuffs Medical Center
KOLs Agree! PRECISE supports Chest Pain Guidelines, CCTA+FFRCT Pathway good for patient care, cath lab efficiency
PRECISE 1 Year Results Quick Summary with Pam Douglas
Webinar: This panel of leading experts discusses insights from the PRECISE Trial 1-Year data, how the findings relate to the 2021 AHA/ACC Chest Pain Guidelines, and what the data tell us about different strategies for the evaluation and diagnosis of coronary artery disease. Featuring Dr. Pamela S. Douglas, Dr. Maros Ferencik, and Dr. Gregg W. Stone
The Precision Pathway, centered around CCTA+FFRCT, achieved its primary endpoint by significantly reducing the composite of all-cause death, nonfatal MI, or catheterization without obstructive disease relative to Traditional Testing at 1 year.
Precision Pathway compared to Traditional Testing:
Global Sites
Patients
Risk scoring to defer testing for low-risk patients.3
CCTA with selective FFRCT4 for elevated risk patients.
Functional testing (stress nuclear and stress echo) and Invasive Coronary Angiography (ICA).
More accurate non-invasive diagnosis
Fewer unnecessary tests
Reduced long-term risk by increasing preventive therapies5
Randomized into one of two pathways.
Randomization stratified by site, PROMISE Minimal Risk Score (Low Risk vs. Elevated Risk), and intended first test (if randomized to Traditional Testing).
All subsequent care and testing decisions made by site clinician.
Guideline-directed medical management recommended for all.
Primary Endpoint (1 year)
Death, Nonfatal MI, Cath without obstructive CAD
Secondary Endpoints
Death, Nonfatal MI, Unplanned CV Hospitalizations, Radiation, Preventive Medication Use, Cath Yield, Resource Use, Quality of Life
REFERENCES
The information provided by the HeartFlow FFRCT Analysis, RoadMap Analysis, and Plaque Analysis from the HeartFlow ONE platform and the HeartFlow Planner is intended to be used in conjunction with the patient's clinical history, symptoms and other diagnostic tests, as well as the clinician's professional judgment. The HeartFlow FFRCT Analysis, RoadMap Analysis, Plaque Analysis and HeartFlow Planner may not be appropriate for all patients. See their respective indications for use for more information. The HeartFlow FFRCT Analysis has received FDA Clearance, is CE-Marked, and is commercially available in the United States, Europe, Japan and Canada. The RoadMap Analysis and Plaque Analysis have received FDA Clearance and are commercially available in the United States. The HeartFlow Planner has received FDA Clearance and is commercially available in the United States.
© 2023 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？
